252 related articles for article (PubMed ID: 25670913)
21. Modern management of malignant pleural mesothelioma.
Patel SC; Dowell JE
Lung Cancer (Auckl); 2016; 7():63-72. PubMed ID: 28210162
[TBL] [Abstract][Full Text] [Related]
22. Clinical diagnosis of malignant pleural mesothelioma.
Bianco A; Valente T; De Rimini ML; Sica G; Fiorelli A
J Thorac Dis; 2018 Jan; 10(Suppl 2):S253-S261. PubMed ID: 29507793
[TBL] [Abstract][Full Text] [Related]
23. Emerging drugs for mesothelioma.
Scagliotti GV; Selvaggi G
Expert Opin Emerg Drugs; 2007 Mar; 12(1):127-37. PubMed ID: 17355218
[TBL] [Abstract][Full Text] [Related]
24. Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma.
Zhang W; Wu X; Wu L; Zhang W; Zhao X
Ann Transl Med; 2015 Aug; 3(13):182. PubMed ID: 26366399
[TBL] [Abstract][Full Text] [Related]
25. [Prognosis, staging and therapy of malignant pleural mesothelioma].
Neumeister W; Gillissen A; Rasche K; Theile A; Müller KM; Schultze-Werninghaus G
Med Klin (Munich); 2002 Aug; 97(8):459-71. PubMed ID: 12229245
[TBL] [Abstract][Full Text] [Related]
26. Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.
Al-Taei S; Salimu J; Lester JF; Linnane S; Goonewardena M; Harrop R; Mason MD; Tabi Z
Lung Cancer; 2012 Aug; 77(2):312-8. PubMed ID: 22498111
[TBL] [Abstract][Full Text] [Related]
27. [Exploratory study on the detection of markers for diagnosing early-stage malignant mesothelioma].
Fukuoka K; Tanaka F; Tsujimura T; Hashimoto-Tamaoki T; Hasegawa S; Nakano T
Nihon Eiseigaku Zasshi; 2011 May; 66(3):553-7. PubMed ID: 21701086
[TBL] [Abstract][Full Text] [Related]
28. Treatment of malignant mesothelioma.
Jaklitsch MT; Grondin SC; Sugarbaker DJ
World J Surg; 2001 Feb; 25(2):210-7. PubMed ID: 11338024
[TBL] [Abstract][Full Text] [Related]
29. [Immunotherapy and malignant mesothelioma: clinical perspectives].
Grégoire M; Ebstein F
Bull Cancer; 2007 Jan; 94(1):23-31. PubMed ID: 17237002
[TBL] [Abstract][Full Text] [Related]
30. [Therapeutic strategies for resectable malignant pleural mesothelioma].
Hasegawa S
Nihon Geka Gakkai Zasshi; 2009 Nov; 110(6):338-42. PubMed ID: 19999568
[TBL] [Abstract][Full Text] [Related]
31. Malignant pleural mesothelioma.
Ho L; Sugarbaker DJ; Skarin AT
Cancer Treat Res; 2001; 105():327-73. PubMed ID: 11224994
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy and radiation therapy for malignant pleural mesothelioma.
Alley EW; Katz SI; Cengel KA; Simone CB
Transl Lung Cancer Res; 2017 Apr; 6(2):212-219. PubMed ID: 28529903
[TBL] [Abstract][Full Text] [Related]
33. [Malignant pleural mesothelioma: diagnosis and treatment].
Delourme J; Dhalluin X; Cortot AB; Lafitte JJ; Scherpereel A
Rev Pneumol Clin; 2013 Feb; 69(1):26-35. PubMed ID: 23333048
[TBL] [Abstract][Full Text] [Related]
34. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma.
Pass HI; Temeck BK; Kranda K; Thomas G; Russo A; Smith P; Friauf W; Steinberg SM
Ann Surg Oncol; 1997 Dec; 4(8):628-33. PubMed ID: 9416409
[TBL] [Abstract][Full Text] [Related]
35. Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis.
Zhao ZY; Zhao SS; Ren M; Liu ZL; Li Z; Yang L
Oncotarget; 2017 Nov; 8(59):100640-100647. PubMed ID: 29246008
[TBL] [Abstract][Full Text] [Related]
36. Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date.
Levin PA; Dowell JE
Onco Targets Ther; 2017; 10():2057-2066. PubMed ID: 28435296
[TBL] [Abstract][Full Text] [Related]
37. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
38. Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation.
Burt BM; Bader A; Winter D; Rodig SJ; Bueno R; Sugarbaker DJ
Clin Cancer Res; 2012 Mar; 18(6):1568-77. PubMed ID: 22261806
[TBL] [Abstract][Full Text] [Related]
39. The role of intracavitary therapies in the treatment of malignant pleural mesothelioma.
Bertoglio P; Aprile V; Ambrogi MC; Mussi A; Lucchi M
J Thorac Dis; 2018 Jan; 10(Suppl 2):S293-S297. PubMed ID: 29507798
[TBL] [Abstract][Full Text] [Related]
40. The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
Pignochino Y; Dell'Aglio C; Inghilleri S; Zorzetto M; Basiricò M; Capozzi F; Canta M; Piloni D; Cemmi F; Sangiolo D; Gammaitoni L; Soster M; Marchiò S; Pozzi E; Morbini P; Luisetti M; Aglietta M; Grignani G; Stella GM
BMC Cancer; 2015 May; 15():374. PubMed ID: 25952930
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
